Clinical trials: active, not recruiting
Kidney Cancer, Stage III Renal Cell Cancer AJCC v8
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
This phase II trial studies how well lenvatinib and pembrolizumab before surgery work in treating patients with kidney cancer that has spread from its original site of growth to nearby tissues or lymph nodes but has not spread to…
- Conditions
- Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT04393350
- Testing
- Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Breast Cancer
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
- Trial name
- DTP (NCT03820141)
- Testing
- Durvalumab, Trastuzumab, Pertuzumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- The Methodist Hospital Research Institute
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome
The Budesonide in Babies (BiB) Trial
This is a Phase 3, randomized, masked, active-controlled, multicenter trial designed to determine whether early intratracheal administration of a combination of budesonide with surfactant, as compared to surfactant alone, will…
- Conditions
- Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
- Trial name
- BiB (NCT04545866)
- Testing
- budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
- Where
- 19 sites in United States
- Volunteers
- 642 people
- Sponsor
- NICHD Neonatal Research Network
Cancer
A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors
This research study aims to explore the feasibility and acceptability of an adapted resiliency group program, called the Relaxation Response Resiliency Program (3RP-AYA), to reduce stress and promote stress-management among…
- Trial name
- NCT03768336
- Testing
- Waitlist control, 3RP-AYA
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
This is a pilot phase 2 study investigating the safety and efficacy of ibrutinib combined with short-course fludarabine in previously untreated CLL patients.
- Trial name
- NCT02514083
- Testing
- Ibrutinib, Fludarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase Ib/2 trial studies how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor…
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission
- Trial name
- NCT03192397
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
Peripheral Vascular Diseases
Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels
The primary objective of the VBX 17-04 registry is to collect post-market safety and performance data of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) in peripheral vessels in patients who require…
- Trial name
- EXPAND (NCT03720704)
- Testing
- GORE VIABAHN VBX Balloon Expandable Endoprosthesis
- Where
- 11 sites in France, Germany and 3 more
- Volunteers
- 280 people
- Sponsor
- W.L.Gore & Associates
Rheumatoid Arthritis
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or…
- Trial name
- RESET-RA (NCT04539964)
- Testing
- Implant Procedure, Conventional Synthetic DMARD, Active stimulation
- Where
- 42 sites in United States
- Volunteers
- 243 people
- Sponsor
- SetPoint Medical Corporation
Severe Aplastic Anemia
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells.
- Trial name
- NCT01623167
- Testing
- Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to Month 3, Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Treatment Resistant Depression
Epidural Cortical Stimulation for Depression
Objective: Chronic epidural cortical stimulation (ECS) involves the neurosurgical placement of an electric wire on the surface of the brain with intermittent activation.
- Trial name
- EpCS-D (NCT00565617)
- Testing
- Synergy, Epidural cortical stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Multiple System Atrophy
A Study of Lu AF82422 in Participants With Multiple System Atrophy
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
- Trial name
- AMULET (NCT05104476)
- Testing
- Lu AF82422
- Where
- 19 sites in United States, Japan
- Volunteers
- 64 people
- Sponsor
- H. Lundbeck A/S
Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
This is a Phase II, single institution open-label, non-randomized monotherapy study to evaluate the clinical efficacy and durable disease control of PCI-32765 administered to patients with relapsed/refractory CLL/SLL/PLL of all…
- Conditions
- Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
- Trial name
- NCT01589302
- Testing
- ibrutinib, Correlative laboratory samples, quality of life assessment
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Kami Maddocks, MD
Symptomatic Severe Aortic Stenosis
Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation
Evaluation of TAVR using the NAVITOR valve in a Global Investigation.
- Trial name
- VANTAGE (NCT04788888)
- Testing
- Navitor Transcatheter Aortic valve and FlexNav Delivery system
- Where
- 37 sites in Australia, Austria and 9 more
- Volunteers
- 434 people
- Sponsor
- Abbott Medical Devices
Breast Cancer
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).
- Trial name
- FINER (NCT04650581)
- Testing
- Ipatasertib, Fulvestrant
- Where
- 39 sites in Australia, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- Canadian Cancer Trials Group
Melanoma
Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma
Effective adjuvant treatment can increase cure in patients with high-risk resected melanoma. High dose interferon is a standard of care in the adjuvant setting but is highly toxic and marginally effective.
- Trial name
- NCT02656706
- Testing
- Ipilumumab, Nivolumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Brown University
Prostate Adenocarcinoma
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
This phase 2 trial studies radium Ra 223 dichloride, hormone therapy and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body.
- Trial name
- NCT03361735
- Testing
- Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Squamous Cell Carcinomas
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups.
- Trial name
- NCT01706939
- Testing
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
- Conditions
- Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
- Trial name
- NCT04869137
- Testing
- Lenvatinib Oral Product, Pembrolizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.